4DMedical (4DX) Investor Update summary

Market opportunity and technology limitations

• Global lung health spending is around $1 trillion annually, with 4% on diagnostics, dominated by outdated technologies like X-ray, CT, and nuclear medicine VQ.

• Current diagnostic tools fail to reliably detect early-stage diseases such as COPD, silicosis, and deployment-related respiratory conditions.

• Unexplained dyspnea affects 9.5% of adults, leading to costly and inefficient patient pathways and delayed care.

• The U.S. faces a $600 billion annual problem in respiratory diagnostics, exacerbated by issues like burn pit exposure among veterans.

Product innovation and portfolio expansion

• Proprietary software enhances existing CT images to visualize lung ventilation and perfusion, adding significant value for clinicians and patients.

• Product suite expanded from a single X-ray-based solution to a comprehensive portfolio, including CT-based LVAS and products from the Imbio acquisition.

• The suite now covers pulmonary and cardiovascular diagnostics, offering quantification and workflow enhancements.

Commercial progress and partnerships

• Revenue run rate has grown to over $6 million per year, driven by the expanded product suite and market penetration.

• Achieved U.S. Medicare reimbursement of $650 per CT LVAS scan, significantly above industry averages.

• Expanded presence in Australia and secured a master reseller agreement with Philips, whose sales team now actively markets the portfolio.

• FDA approval for new products and ongoing interest from the U.S. Department of Defense.